PIK3CG and breast carcinoma: Besides pan-PI3K inhibitors, a phase I trial was conducted with the p110α-specific alpelisib inhibitor in association with trastuzumab emtansine (TDM-1) in trastuzumab-resistant breast cancer patients [97].